Singapore markets close in 1 hour 55 minutes

(NOT.HM)

Hamburg - Hamburg Delayed price. Currency in USD
Add to watchlist
80.190.00 (0.00%)
As of 02:05PM CEST. Market open.
Full screen
Previous closeN/A
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's rangeN/A - N/A
52-week range75.20 - 75.20
VolumeN/A
Avg. volume0
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria

    There is currently no evidence-based treatment for the smallest babies with malaria The CALINA study tested a new ratio and dose of Coartem® (artemether- lumefantrine) to account for metabolic differences in babies under 5 kg The CALINA trial indicated that the new formulation has good efficacy and safety, and the data have been submitted for regulatory review Basel, April 24, 2024 – Novartis and Medicines for Malaria Venture (MMV) announce positive data from their phase II/III CALINA study, dem

  • GlobeNewswire

    Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors

    Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric (ages 12-17) and adult patients Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a rare cancer that is often unresectable and commonly diagnosed in the late stages of diseaseNovartis, a leader in radioligand therapy (RLT), is investigating a portfolio of RLTs to treat a broad range of cancers, including GEP-NETs, lung, prostate, breast, colon, bra

  • Yahoo Finance Video

    Novartis raises full-year guidance on Q1 beat, drug sales

    Shares of Novartis (NVS) are soaring in Tuesday's pre-market trading session — holding onto steady gains into the market open — after the Swiss pharmaceutical giant reported better-than-expected first-quarter earnings and raised its full-year guidance. The robust financial performance was driven primarily by strong sales of the company's innovative heart failure and psoriasis treatment drugs. Yahoo Finance Health Reporter Anjalee Khemlani breaks down the details. For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Angel Smith